Journal article
Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2)
KK Broman, T Hughes, L Dossett, J Sun, D Kirichenko, MJ Carr, A Sharma, EK Bartlett, AAG Nijhuis, JF Thompson, TJ Hieken, L Kottschade, J Downs, DE Gyorki, E Stahlie, A van Akkooi, DW Ollila, J Frank, Y Song, G Karakousis Show all
Cancer | WILEY | Published : 2021
DOI: 10.1002/cncr.33483
Abstract
Background: For patients with sentinel lymph node (SLN)-positive cutaneous melanoma, the Second Multicenter Selective Lymphadenectomy trial demonstrated equivalent disease-specific survival (DSS) with active surveillance using nodal ultrasound versus completion lymph node dissection (CLND). Adoption and outcomes of active surveillance in clinical practice and in adjuvant therapy recipients are unknown. Methods: In a retrospective cohort of SLN-positive adults treated at 21 institutions in Australia, Europe, and the United States from June 2017 to November 2019, the authors evaluated the impact of active surveillance and adjuvant therapy on all-site recurrence-free survival (RFS), isolated no..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
This work was supported in part by the Biostatistics and Bioinformatics Shared Resource at the H. Lee Moffitt Cancer Center and Research Institute, a National Cancer Institute-designated comprehensive cancer center (P30-CA076292).